Abstract

The delivery of anticancer therapeutics to solid tumors remains a critical problem in the treatment of cancer. This study reports a new methodology to target a temperature-responsive macromolecular drug carrier, an elastin-like polypeptide (ELP) to solid tumors. Using a dorsal skin fold window chamber model and intravital laser scanning confocal microscopy, we show that the ELP forms micron-sized aggregates that adhere to the tumor vasculature only when tumors are heated to 41.5 degrees C. Upon return to normothermia, the vascular particles dissolve into the plasma, increasing the vascular concentration, which drives more ELPs across the tumor blood vessel and significantly increases its extravascular accumulation. These observations suggested that thermal cycling of tumors would increase the exposure of tumor cells to ELP drug carriers. We investigated this hypothesis in this study by thermally cycling an implanted tumor in nude mice from body temperature to 41.5 degrees C thrice within 1.5 h, and showed the repeated formation of adherent microparticles of ELP in the heated tumor vasculature in each thermal cycle. These results suggest that thermal cycling of tumors can be repeated multiple times to further increase the accumulation of a thermally responsive polymeric drug carrier in solid tumors over a single heat-cool cycle. More broadly, this study shows a new approach--tumor thermal cycling--to exploit stimuli-responsive polymers in vivo to target the tumor vasculature or extravascular compartment with high specificity.

Highlights

  • The treatment of cancer with anticancer agents is typically limited by toxic side effects in normal tissues

  • We show a new method of tumor cell targeting that we term ‘‘tumor thermal cycling’’ that can further increase the accumulation of thermally responsive polymer drug carriers in solid tumors

  • The tumor was heated to 41.5jC, and bright green aggregates were clearly visible within the tumor, indicating that the phase transition of the thermally sensitive ELP1 was triggered in vivo, in agreement with a previous study [24]

Read more

Summary

Introduction

The treatment of cancer with anticancer agents is typically limited by toxic side effects in normal tissues. In addition to the enhanced permeability and retention effect, macromolecular drug carriers are an attractive drug delivery vehicle because they have longer plasma half-lives, reduced normal tissue toxicity, activity against multiple drug-resistant cell lines, and greater solubility than free drug [8, 9]. These attributes often result in the better efficacy of macromolecular drug carriers as compared with low molecular weight drugs [8, 9]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.